AUG 19, 2026 · PHASE 2 TRIAL
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
ClinicalTrials.gov
Phase 2 neoadjuvant trial of an investigational PD-L1 inhibitor combined with chemotherapy in early HR+/HER2- breast cancer; no results reported in this registry record.
Reported
Planned enrollment357
PhasePHASE 2
Primary outcome measure 1PCR rate at the time of surgery